9Furlant M,Brollo L,Lugatti g,et al.Pharmacokinetic aspects of Levofloxcin 500mg once daily during sequential intravenous/oral therapy inpatients with lower respiratory tract in fections.Antimi-crob Agents chemother,2003,51(1):101-106.
5Quintiliani R, Cooper BW, Bficeland LL. Economic impact of streamlining antibiotic administration. Am J Med, 1987,27,82(4A) : 391-394.
6Ball P. Efficacy and safety of levofloxacin in the context of other contemporary fluroquinolones: A review. Current Therapeutic Research ,2003,64(9) :646-661.
7Pea F, Fudanut M. Levofloxacin PK/PD:from sequential therapy model to high dosage for critical patients. J Chemother,2004,16 Suppl 2:8-10.
8Zacher L 见:Gate RH 主编 汪明明 崔速南 译.社区获得性肺炎:头号公敌[A].见:Gate RH,主编,汪明明,崔速南,译.美国最新临床医学问答感染性疾病[C].北京:海洋出版社,2000.431-439.
9Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs, 1998,55:31-45.
10Battleman DS,Callahan M,Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia:link between quality of care and resource utilization. Arch Intern Med ,2002,162:682-688.
